On November 18, 2015 Cancer Research Technology (CRT) is pleased to reported that a major drug discovery feasibility study with Merck Serono, the biopharmaceutical business of Merck, focused on the role of the Hippo pathway in cancer (Press release, Cancer Research Technology, NOV 18, 2015, View Source [SID1234523508]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under normal circumstances the Hippo pathway regulates cell size, controlling the growth of tissues during development and regeneration. Deregulation of the Hippo pathway has been implicated in inducing tumours in a broad range of cancers, making it a potentially attractive target for cancer therapy.

Scientists from CRT Discovery Laboratories (CRT-DL) will work together with Merck Serono scientists to validate the target, using CRT-DL’s expertise in building cell screening assays.

The establishment of this relationship exemplifies CRT-DL’s drug discovery model of bringing together complementary skills from academia and industry to build on novel insights within an exciting area of biology, which we hope will lead to new therapies for cancer patients.